Introduction: The mechanism of oxaliplatin (OXA) induced pulmonary toxicity is not fully understood.

Aim of the study: The present study was designed to investigate the pulmonary toxicity of OXA that has been reported in previous studies. Study design: animal experiments.

Material and methods: A total of 40 female Wistar rats were divided into 5 groups. In group 1, 5% glucose was injected intra-peritoneally; then the rats were sacrificed on day 14. OXA was administered in groups 2, 3, 4, and 5; then the animals were sacrificed on day 7 in group 2, day 14 in group 3, day 28 in group 4 and day 48 in group 5. The groups were further categorized as short-term administration and long-term administration groups. Furthermore, tissue glutathione peroxidase (GPX) activity was measured in all rats.

Results: The mean GPX activities were 0.66 U/mg in the sham group, 0.74 U/mg in the short-term groups, and 0.74 U/mg in the long-term groups. We found that long-term OXA administration causes pulmonary toxicity resulting in increased intra-alveolar/interstitial macrophages and interstitial pneumonia. Similarly, we found reduced and permanent tissue GPX activity in rats that received OXA in higher doses and for a long term.

Conclusions: Long-term OXA therapy causes toxic changes in the lung tissue.

Key words: glutathione peroxidase, oxaliplatin, pulmonary toxicity, rat, pulmonary pathology.

Contemp Oncol (Pozn) 2019; 23 (3): 151–156
DOI: https://doi.org/10.5114/wo.2019.89242

Evaluation of oxaliplatin-induced pulmonary toxicity in rats

Serdar Kalemci1, Ozgür Tanrıverdi2, Abdullah Şimşek1, Salıha Aksun4, Ozgür I. Celik5, Sabri Barutca6, Arife Zeybek7, Buket Demirci8

1Department of Chest Diseases, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
2Department of Medical Oncology, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
3Department of Chest Diseases, Sağlık Bilimleri University, Yüksek İhtisas Education and Research Hospital, Bursa, Turkey
4Department of Medical Biochemistry, Faculty of Medicine, Katip Celebi University, Izmir, Turkey
5Department of Pathology, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
6Department of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey
7Department of Thoracic Surgery, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
8Department of Medical Pharmacology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey

Introduction

Following cisplatin and carboplatin, oxaliplatin (OXA) has emerged as the third generation platinum-based chemotherapeutic drug that has been approved by the United States Food and Drug Administration (FDA) [1]. It causes cell death by binding to DNA and forming cross-links. This in turn prevents DNA replication and transcription [1, 2]. This mechanism is similar for all platinum-based cytotoxic drugs that influence the production of intracellular reactive oxygen species (ROS) upon DNA and mitochondrial damage in malignant cells. In addition, OXA interacts with reduced glutathione (GSH), and depletion of GSH is one of the necessary pathways for the cytotoxic effect obtained through ROS production [2–4].

Since the FDA’s approval in 2002, OXA has been commonly used not only in the treatment of stage III and IV colorectal cancer but also in systemic treatment of some other cancer types such as ovarian, breast, stomach, pancreas, testicular cancers and non-Hodgkin lymphoma [1, 5]. As its clinical use became widespread, the information related to the frequency and management of OXA-induced adverse effects also increased. Although it appears structurally similar to cisplatin, OXA consists of a 1,2-diaminocyclohexane bear ligand which results in a different adverse effects profile than cisplatin [4]. The nephrotoxicity and ototoxicity frequencies are lower than those of cisplatin, and the myelosuppression frequency is lower than that of carboplatin [6]. Although it varies significantly, OXA-induced neurotoxicity is an important side effect seen in most patients. The neurotoxicity experienced as a result of this drug involves both acute and chronic sensorial and motor neuropathies [6, 7]. Hematological and gastrointestinal toxicity should be kept in mind as other frequent side effects [7]. However, previous studies have not defined the profile and the prevalence of OXA-induced pulmonary toxicity yet.

Treatment-related pulmonary damage occurs in approximately 5–10% of cancer patients who receive chemotherapy [8]. It most frequently presents as pneumonitis/fibrosis and hypersensitivity pneumonitis. While bleomycin, mitomycin, cyclophosphamide, and busulfan comprise the most common reasons for pneumonitis/fibrosis, paclitaxel, docetaxel and methotrexate are typically responsible for hypersensitivity pneumonitis [8, 9]. Current-
ly available data in the literature related to OXA-induced pulmonary toxicity are based mostly on case reports and pulmonary toxicity patterns, so the underlying mechanism and associated factors have not been described comprehensively [8, 9]. Animal studies on OXA-induced pulmonary toxicity are also very limited [10–13].

In this study, we aimed to demonstrate the short- and long-term effects of OXA treatment on lung tissue. Additionally, if there were any significant findings in biochemical and histopathological parameters, the reversibility of the relevant findings was also studied within the follow-up periods after the last administration of the drug.

**Material and methods**

**Animals and experimental design**

A total of 40 female 6–8 month old Wistar rats were obtained from the Experimental Animal Center of our university and all experiments were performed according to the principles and guidelines of the University Ethical Committee (UEC). The rats were kept in an environmentally controlled room at constant temperature (21 ±1°C) and humidity (75 ±5%) under a 12 h light/dark cycle. The animals were acclimatized for 1 week prior to the study and had free access to standard laboratory feed and water ad libitum. The study was originally planned to investigate OXA-auto-toxicity; however, in order to reduce the number of animals used in medical research, a new ethics committee approval was obtained to evaluate the pulmonary toxicity of the lung tissues of the animals (HADYEK/2014/162).

The animals were randomly divided into five study groups (Table 1). Each group consisted of 8 animals. Prior to intra-peritoneal (i.p.) administration, the OXA (Eloxatin, Sanofi, U.S.) dose of 4 mg/kg was diluted in a 5% glucose solution:

- **group 1**: sham group, glucose 5%, 1 ml was administered i.p. on days 1, 3, and 5 and the rats were sacrificed on day 14;
- **group 2**: OXA was injected on days 1, 3, and 5 and the rats were sacrificed on day 7;
- **group 3**: OXA was injected on days 1, 3, and 5 and the rats were sacrificed on day 14;
- **group 4**: OXA was injected twice a week (Monday and Thursday) for 4 weeks and the rats were sacrificed on day 28;
- **group 5**: OXA was injected twice a week (Monday and Thursday) for 4 weeks; after the completion of the injections, the rats were sacrificed on day 48 [8].

The OXA dosage was adjusted according to the study by Caveletti et al. [14] and no animals were lost during the study procedures. The research aimed to determine both acute and chronic toxic effects through the dosages, which did not exceed the lethal dosage (15 mg/kg per week). The groups were further classified into three groups according to the treatment courses: sham group (group 1), short-term group (groups 2 and 3), and long-term group (groups 4 and 5) (Table 1). Groups 2 and 3 were monitored for a short period (7–14 days) following OXA injection; groups 4 and 5 were monitored for a longer period (28–48 days) after OXA injections to examine the reversibility of possible acute damage.

We sacrificed the rats under anesthesia at specified times determined for each group (Table 1). Anesthesia was induced by a single i.p. injection of ketamine (Ketalar, Pfizer, 50 mg/kg) and xylazine (Alfazyne 2%, 5 mg/kg). The blood was obtained by cardiac puncture and the lungs were harvested and kept at –80°C for histopathological evaluation.

**Preparation of tissue specimens**

After being weighed, the lung tissues were processed and kept on ice at all times with 50 mM phosphate buffer (pH = 7.4) at appropriate rates and homogenized with a homogenizer (Randox Reagents Rx Series, Northern Ireland) for 10 minutes at 8000 rpm. After homogenization, sonication (Abbott C8000, United States) was performed to strengthen the effect of the homogenization procedure. The homogenate was centrifuged in a cooled centrifuge at +4°C for 10 minutes at 6000 rpm, and the supernatant fraction was removed.

**Determination of glutathione peroxidase levels**

The glutathione peroxidase (GPX) method was based on the procedure as described by Paglia and Valentine [15]. GPX catalyzes the oxidation of GSH by cumene hydroper-
in the presence of glutathione reductase and NADPH, the oxidized GSH (GSSG) is immediately converted to its reduced form (GSH) with a concomitant oxidation of NADPH to NADP as shown below:

\[
2 \text{GSH} + \text{ROOH} + \text{GSH-Px} \rightarrow \text{ROH} + \text{GSSG} + \text{H}_2\text{O} \\
\text{GSSG} + \text{NADP}^+ + \text{H}^+ + \text{GR} \rightarrow \text{NADPH}^+ + 2 \text{GSH}
\]

Measurement of decrease in absorbance was performed at 340 nm (Ransel Glutathione Peroxidase, Randox, United Kingdom). GPX level was measured in tissue protein homogenate using an Abbott protein kit auto-analyzer (Abbott, Abbott, United States), and expressed as mg/dl. GPX activity was expressed as U/l. Lung tissue GPX activity results were given as U/mg tissue protein.

### Histopathological examination of lungs

The lung samples of the rats in each group were fixed in 10% neutral buffered formalin for 24 hours. Rinsing was done with tap water, and then serial dilutions of alcohol (methyl, ethyl and absolute ethyl) were used for dehydration. The specimens were cleared in xylene and embedded in paraffin at 56°C in a hot-air oven for 24 hours. Paraffin beeswax tissue blocks were prepared for sectioning at 5 μm thickness by a microtome (Leica Tissue Microtome Model RM 2125T; Leica Microsystems-Nussloch GmbH, Germany). Lung tissues were stained with hematoxylin and eosin (H&E) and examined by light microscopy (Olympus Clinical Microscope Model BX46, Olympus Cooperation, Germany). Along with that, Masson-Trichrome stain was used for histopathological examination.

Pulmonary damage due to OXA was assessed based on six parameters: 1) interstitial pneumonia (the lymphocytic infiltration in the parenchyma of the lung), 2) interstitial fibrosis (increased collagen in the parenchyma of the lung around the alveoli), 3) parenchymal hemorrhage for acute or chronic damage, 4) intra-alveolar/interstitial macrophage presence (presence of macrophages both in and between the alveoli), 5) eosinophil existence (presence of eosinophils both in and between the alveoli), and 6) granuloma existence (presence of granulomas in the parenchyma of the lung around the alveoli).

All parameters were separated into 4 sections in terms of their severity and scored semi-quantitatively. The scoring system was as follows: 0: absent (no interstitial lymphocytic inflammation, no fibrosis, no type 2 pneumocyte infiltration, no macrophages, no eosinophils, and no granulomas), 1: mild (a few lymphocytes, type 2 pneumocytes, macrophages, eosinophils, granulomas, and minimal fibrosis), 2: moderate (between score 1 and score 3), and 3: severe (diffuse infiltration of excessive number of lymphocytes, type 2 pneumocytes, macrophages, eosinophils, granulomas and excessive diffuse fibrosis) [16]. We also further analyzed the percentages of histopathological findings regardless of the severity grading (as 1: present vs. 0: absent) between three groups (sham group, short-term and long-term OXA administered groups) with the \( \chi^2 \) test.

### Statistical analysis

The SPSS 22.0 (IBM Statistics for Windows version 22, IBM Corporation, Armonk, New York, United States) software was used in the analysis of data. The conformity of the data to normal distribution was analyzed based on the Shapiro-Wilk test. The one-way analysis of variance test (ANOVA, Robust test: Brown-Forsythe) was used in comparison of multiple independent groups. For comparison of categorical data, Pearson’s \( \chi^2 \) test was used based on the Monte Carlo simulation technique. The categorical data were classified in numbers (n) and percentages (%). The Jonckheere-Terpstra test was used in comparisons between reduced-dose/short-term (groups 2 and 3), higher-dose/long-term administered groups (groups 4 and 5) and the sham group. The Mann-Whitney U test was used to compare the tissue GPX levels between groups as a post-hoc test if the \( p \) value was significant in the Kruskal-Wallis test. The data were analyzed at a 95% confidence level, two-tailed and a \( p \) value of less than 0.05 was accepted as statistically significant.

### Results

All of the animals that received OXA were able to complete the study and no death was observed. There was no significant difference between study groups in terms of weight change throughout the study (\( p > 0.05 \)).

### Histopathological results

Total OXA doses and application scheme and classification of the study groups according to OXA administration are given in Table 1.

| Features                              | Group 1 (sham group) | Groups 2 and 3 (low-dose/short-term) | Groups 4 and 5 (high-dose/long-term) | \( p^* \) |
|---------------------------------------|----------------------|--------------------------------------|-------------------------------------|--------|
| Interstitial pneumonia                | 0 (0–0)              | 0 (0–1)                              | 0 (0–2)                             | 0.029* |
| Interstitial fibrosis                 | 0 (0–0)              | 0 (0–1)                              | 0 (0–1)                             | 0.103  |
| Parenchymal hemorrhage                | 0 (0–0)              | 0 (0–1)                              | 0 (0–1)                             | 0.593  |
| Intra-alveolar/interstitial macrophage | 0 (0–0)              | 0 (0–1)                              | 0 (0–1)                             | 0.008**|
| Presence of eosinophils               | 0 (0–0)              | 0 (0–1)                              | 0 (0–1)                             | 0.020* |
| Presence of granuloma                 | 0 (0–0)              | 0 (0–1)                              | 0 (0–1)                             | 0.109  |

* median (min–max) compared with Jonckheere-Terpstra test, post-hoc comparisons; \(^\ast\) sham vs. low-dose/short-term, \(^\ast\) sham vs. high-dose/long-term group, \(^\ast\) low-dose/short-term vs. high-dose/long-term group

---

Table 2. Comparison of histopathological features of study groups re-classified based on OXA doses and application schema
When the sham group was compared with the lower-dose/short-term and higher-dose/long-term OXA administration groups, no significant difference was found between the groups in terms of interstitial fibrosis (p > 0.05), parenchymal hemorrhage (p > 0.05), or granuloma presence (p > 0.05). However, the rats that received higher-dose/long-term OXA had significantly increased intra-alveolar/interstitial macrophage (p < 0.05) and eosinophil (p < 0.05) presence and a higher rate of interstitial pneumonia (p < 0.05) compared to the sham group and low-dose/short-term group (Table 2). In addition, we compared all groups (sham vs. low-dose/short-term vs. high-dose/long-term groups) in terms of the frequencies of histopathological findings regardless of the severity grading (as 1: present or 0: absent) with χ² test and found similar results with the former comparison. No significant difference was found between three groups regarding the frequencies of interstitial fibrosis, parenchymal hemorrhage, or presence of granuloma whereas the frequency of interstitial pneumonia and the presence of intra-alveolar/interstitial macrophage and eosinophil were increased in the high-dose/long-term group compared with the sham group (Table 3).

The histopathological features used to describe pulmonary OXA toxicity under the light microscopy were depicted in Figure 1.

Biochemical results

According to the classification based on the total dose and application length of OXA injection, we found that there was significantly reduced tissue GPX activity in rats that were given higher-dose/long-term OXA compared to the sham group. The mean GPX activities were 0.66 U/mg in the sham group, 0.74 U/mg in the short-term groups, and 0.74 U/mg in the long-term groups (Table 4). The tissue GPX level was significantly higher in the lower-dose/short-term group compared with the sham group (p = 0.049).

Discussion

In our study, we found that the rats that received short-term OXA administration had significantly higher GPX activity in the lung tissue. Initially this suggests that the anti-oxidant system was activated and during this period, drug therapy was counteracted by the lungs. Meanwhile, the antioxidant system of the lungs was compromised with the continuation of therapy. When the chronic therapy was discontinued, in other words, after the elimination of the effect that created oxidative stress (despite the time elapsed) the impaired antioxidant balance could not be restored. No histopathological findings were detected as a response to the increase in the antioxidant system during the initial period. In rats that received higher-dose/long-term OXA therapy, histopathological findings indicating chronic pulmonary toxicity such as increased interstitial pneumonia and interstitial/intra-alveolar macrophage and eosinophil counts proceeded consistently with the decrease in lung tissue GPX activity.

In the first efficacy and safety studies of OXA, it was reported that pulmonary toxicity did not develop with the exception of hypersensitivity reaction and dyspnea [17]. However, pulmonary damage was reported in patients with colorectal cancer, who recently received the FOLF-OX regimen, composed of OXA, 5-fluorouracil (FU) and folinic acid (FA) [11, 12]. Muneoka et al. [18] reported that pulmonary toxicity did not recur clinically when they administered 5-FU and FA without OXA to patients who had developed pulmonary toxicity after the FOLFOX regimen. In addition, due to the lack of data related to pulmonary toxicity in previous studies related to 5-FU and FA, it was believed that pulmonary side effects in these cases were associated with OXA [18]. In addition, Yague et al. [19] re-

| Features                  | Group 1 (Sham group) n = 7 | Groups 2 and 3 (low-dose/short-term) n = 16 | Groups 4 and 5 (high-dose/long-term) n = 16 | p-value* |
|---------------------------|---------------------------|------------------------------------------|-------------------------------------------|----------|
| Interstitial pneumonia, n (%) | 0 (0)                    | 3 (19)                                   | 6 (38)                                    | 0.044    |
| Interstitial fibrosis      | 0 (0)                    | 2 (13)                                   | 5 (31)                                    | 0.057    |
| Parenchymal hemorrhage     | 0 (0)                    | 1 (6)                                    | 0 (0)                                     | 0.753    |
| Intraalveolar/interstitial macrophages | 0 (0)                  | 0 (0)                                   | 5 (31)                                    | 0.013    |
| Presence of eosinophils    | 0 (0)                    | 0 (0)                                    | 4 (25)                                    | 0.029    |
| Presence of granuloma      | 0 (0)                    | 0 (0)                                    | 2 (13)                                    | 0.132    |

*p for three groups

| Features                  | Group 1 (Sham group) n = 7 | Groups 2 and 3 (Short-term) n = 16 | Groups 4 and 5 (Long-term) n = 16 | p²      |
|---------------------------|---------------------------|-----------------------------------|----------------------------------|--------|
| GPX, U/mg, median (IQR)   | 0.66 (0.62–0.69)          | 0.74 (0.69–0.81)                   | 0.74 (0.63–0.76)                 | 0.049*  |

*p-value of < 0.017 was considered as significant according to Bonferroni correction.

GPX – glutathione peroxidase activity in lung tissue, IQR – interquartile range, *Kruskal-Wallis test, post-hoc pair-wise comparisons with Mann-Whitney U test, # sham group vs. low-dose/short-term (p* = 0.010), * sham group vs. high-dose/long term (p = 0.109), † low-dose/short-term vs. high-dose/long-term (p = 0.429)
Evaluation of oxaliplatin-induced pulmonary toxicity in rats

ported pulmonary toxicity in patients with metastatic colorectal cancer who were given OXA alone. In a case series published in 2012, Prochilo et al. [20] reviewed 30 gastric or colorectal cancer patients and discussed OXA-induced pulmonary fibrosis. Pulmonary fibrosis was not observed in other treatment regimens except for OXA alone (n = 1), FOLFOX regimen combined with bevacizumab (n = 2), OXA combined with capecitabine and bevacizumab treatments (n = 1) [20]. The number of administered chemotherapy cycles varied between 1 to 13 and the OXA dosage and the median number of chemotherapy cycles showed a slight difference between those who developed pulmonary fibrosis and those who did not [20]. However, the limitation of this study was that the risk factors and the number of administered OXA cures in this analysis involving the previous 30 cases could not be determined clearly [20, 21].

Histopathologically organized pneumonia, diffuse alveolar damage and nonspecific interstitial pneumonia were reported in some of the patients with colorectal cancer who received the FOLFOX regimen [11, 12]. Additionally, Wilcox et al. [21] presented evidence of pulmonary toxicity in three patients treated with the FOLFOX regimen who developed interstitial lung disease following chemotherapy. Nevertheless, it is not known whether the incidence of interstitial lung disease development is due to OXA-induced pulmonary toxicity [21].

Although some mechanisms leading to pulmonary toxicity associated with various chemotherapeutics such as bleomycin, mitomycin, busulfan, and taxanes are well understood, it is not yet clear which mechanisms cause OXA-induced pulmonary damage. It was reported that OXA causes GSH depletion and this may be the underlying mechanism of liver damage resulting from hepatic sinusoidal obstruction. Similarly, GSH is an important antioxidant small molecule for human lungs and it may exhibit a protective effect against pulmonary damage by the oxidant/ROS. From this point of view, it may be extrapolated that OXA can cause pulmonary toxicity through GSH depletion in pulmonary tissue [21]. In addition to the significant reduction in pulmonary GPX activity that we observed in the present study, all of the previous reports support the histopathological findings indicating the incidence and progression of chronic toxicity.

The most striking finding of the present study was the substantial increase in eosinophilic pulmonary damage. Gagnadoux et al. [22] have also reported a case with OXA-induced eosinophilic pulmonary damage. Eosinophils are granulocytic cells, which secrete various cytokines, chemokines, and mediators [23]. They become hyper-granulated directly by oxidative stress products and indirectly by inflammatory cells. They also induce tissue damage as a result of granule degradation [24]. This event may be explained with the adaptation of eosinophilic activation of ROS that takes place in the lungs. Based on our results concerning the tissue GPX activity, diminished GPX activity in pulmonary tissue may indicate that the oxidative stress in the lung tissue caused by ROS occurring in association with OXA may also create eosinophilic damage.

Limitations

The most important limitation of our study was the inability to examine pulmonary tissue by electron microscopy, which was due to technical problems and financial limitations. Therefore, further detailed studies incorporating advanced electron microscopy and evaluating various molecular mechanisms will enable us to better identify and understand OXA-induced pulmonary toxicity. This in

Fig. 1. A) Normal lung tissue stained with hematoxylin and eosin (H&E ×100), and Masson trichrome (MTC) stain showing no inflammation, hemorrhage or fibrosis. B) Lymphocytic infiltration is seen in pulmonary parenchyma named as interstitial pneumonitis (H&E ×100). C) Interstitial fibrosis areas due to increased collagen synthesis in pulmonary parenchyma around the alveoli can be seen as blue with Masson trichrome stain (MTC ×100). D) Substantial amount of erythrocytes in the alveolar and interstitial spaces indicating pulmonary parenchymal hemorrhage (H&E ×40). E) A number of macrophages can be seen both in the intra-alveolar and interstitial spaces (arrows) (H&E ×100). F) A number of eosinophils can be seen both in the intra-alveolar and interstitial spaces (arrows) (H&E ×400). G) Depicts a granuloma formation in the pulmonary parenchyma (H&E ×40). H) A number of macrophages can be seen in both intra-alveolar and interstitial spaces together with lymphocytic infiltration in pulmonary parenchyma indicating interstitial inflammation/pneumonitis (H&E ×100).
Conclusions

In conclusion, the mechanism of OXA-induced pulmonary toxicity, which can be diagnosed clinically and radiologically after excluding other potential causes, is not clear yet. This animal study could provide evidence both histologically and biochemically that the long-term administration of OXA can lead to pulmonary toxicity and result in a decrease in lung GPX activity compared with the control group and the short-term implementation of OXA. This may indicate that the increased eosinophil presence in pulmonary tissue due to OXA implementations in the long term may be one of the factors that lead to pulmonary toxicity.

The authors declare no conflict of interest.

References

1. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, William GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist 2004; 9: 8-12.
2. Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 1994; 203: 1175-1180.
3. Laurent A, Nicco C, Chereau C, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005; 65: 948-956.
4. Rabik CA, Dolan ME. Molecular mechanism of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
5. Raghavan D. Testicular Cancer: Maintaining the high cure rate. Oncology (Williston Park) 2003; 17: 218-228.
6. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009; 8: 10-16.
7. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29: 11-20.
8. Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin J Med 2001; 68: 782-795.
9. Dimopoulos I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary Toxicity from novel antineoplastic agents. Ann Oncol 2006; 17: 372-379.
10. Lee EJ, Lee SY, In KH, Kim CH, Park S. Organizing pneumonia associated with oxaliplatin-combined chemotherapy: a case report. Med Princ Pract 2012; 21: 89-92.
11. Ryu CG, Jung EJ, Kim G, Kim SR, Hwang DY. Oxaliplatin-induced pulmonary fibrosis: two case reports. J Korean Soc Coloproctol 2011; 27: 266-269.
12. Watkins J, Slade JH, Phan A, Eng C, Weissferdt A, Overman MI. Fatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer 2011; 10: 198-202.
13. Yoon SY, Robinson CR, Zhang H, Dougherty PM. Spinal astrocyte gap junctions contribute to oxaliplatin induced mechanical hypersensitivity. J Pain 2013; 14: 205-214.
14. Cavaletti G, Tredici G, Petruccio MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001; 37: 2457-2463.
15. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-169.
16. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000; 15: 373-381.
17. Ramanathan RK, Clark JW, Kemeny NE, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003; 21: 2904-2911.
18. Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Hatakeyama K. Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX). Int J Clin Oncol 2009; 14: 457-459.
19. Yagüe XH, Soy E, Merino BQ, Puig J, Fabregat MB, Colomer R. Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol 2005; 7: 515-517.
20. Porchilo T, Abeni C, Bertocchi P, Zaniboni A. Oxaliplatin-induced lung toxicity. Case report and review of the literature. Curr Drug Saf 2012; 7: 179-182.
21. Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med 2008; 102: 273-279.
22. Gagnadoux F, ROIron C, Carrie E, Monnier-Cholley L, Lebeau B. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol 2002; 25: 388-390.
23. Gleich GJ, Adolphson CR. The eosinophilic leukocyte: structure and function. Adv Immunol 1986; 39: 177-253.
24. Khoury P, Grayson PC, Kilon AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol 2014; 10: 474-483.